NF1 and acute lymphoblastic leukemia: In agreement with this, CREBBP mutations have been previously associated with a high incidence of relapse in ALL patients (Mullighan et al., 2011), whereas NF1 mutations do not seem to change overall survival in ALL (Huang et al., 2024).